Pharmabiz18h
Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran
Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran: Cambridge, Massachusetts Saturday, April 5, 2025, 18:00 Hrs [IST] Intellia Therapeu ...
Pharmabiz19h
Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee
Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee: Brisbane, California Saturday, April 5, 2 ...
Pharmabiz21h
Vera Therapeutics completes full enrollment in pivotal ORIGIN phase 3 trial for Atacicept in patients with IgA nephropathy
Brisbane, California Saturday, April 5, 2025, 15:00 Hrs [IST] ...
Pharmabiz23h
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer
EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...
Pharmabiz22h
Clinical Trials Information System designated as WHO primary registry
The Clinical Trials Information System (CTIS) has been designated as a primary registry by the World Health Organisation (WHO) within the International Clinical Trials Registry Platform (ICTRP).